The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.